Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Treatment Response Biomarkers in Asthma and COPD

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Associations between maternal and environmental exposures on atopic disease in the offspring of mothers with asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Unique Aspects of Asthma in Women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The CORTICO-COP trial showed that eosinophil-guided corticosteroid-sparing treatment for acute exacerbation of chronic obstructive pulmonary disease was non-inferior to standard of care and decreased the accumulated dose of systemic corticosteroids that patients were exposed to by approximately 60%. Smoking status has been shown to affect corticosteroid responsiveness. This post hoc analysis investigated whether eosinophil-guided treatment is non-inferior to conventional treatment in current smokers. The main analysis of current smokers showed no significant difference in the primary endpoint, days alive, and out of hospital within 14 days between the control group (mean, 9.8 days; 95% confidence interval (CI), 8.7-10.8) and the eosinophil-guided group (mean, 8.7 days; 95% CI, 7.5-9.9; p = 0.34). Secondary analyses of the number of exacerbations or deaths, the number of intensive care unit admissions or deaths, lung function improvement, and change in health-related quality of life also showed no significant differences between the two groups. The results of a sensitivity analysis of ex-smokers are consistent with the main analysis. Our results suggest that eosinophil-guided treatment is non-inferior to standard of care in current smokers and ex-smokers. Because data on the impact of smoking status on eosinophil-guided treatments are sparse, more randomised trials are needed to confirm our results.

OriginalsprogEngelsk
Artikelnummer2734
TidsskriftJournal of Clinical Medicine
Vol/bind10
Udgave nummer12
ISSN2077-0383
DOI
StatusUdgivet - 21 jun. 2021

ID: 66573543